Biocon Ltd., incorporated in the year 1978, is a Large Cap company (having a market cap of Rs 48180.00 Crore) operating in Pharmaceuticals sector.
Financials
For the quarter ended 31-12-2020, the company reported a Consolidated Total Income of Rs 1878.90 Crore, up 6.74 % from last quarter Total Income of Rs 1760.30 Crore and up 5.33 % from last year same quarter Total Income of Rs 1783.90 Crore. Company has reported net profit after tax of Rs 187.40 Crore in latest quarter.
Investment Rationale
Revenues are expected to grow 32.2% YoY Rs 2089 crore amid low base effect in Biosimilars due to Covid impact in Q4FY20. Subsequently, Biosimilars are expected to grow ~86% YoY (5% QoQ) with sequential growth stemming from increase in Fulphila (Pegfilgrastim) sales. Contract research segment is expected to grow 14% YoY to Rs 693 crore whereas Generics segment is expected to grow 5% YoY. EBITDA margins are expected to improve 233 bps to 22.5% due to better gross margins. Net profit is expected to grow 52.7% YoY to ~Rs 188 crore, amid higher depreciation
Promoter/FII Holdings
Promoters held 60.67 per cent stake in the company as of March 31, 2020, while FIIs held 14.98 per cent, DIIs 7.32 and public and others 17.03 per cent.
